Amundi
CLBT icon

Amundi’s Cellebrite CLBT Stock Holding History

Amundi’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$774K Buy
53,045
+15,784
+42% +$209K ﹤0.01% 1480
2026
Q1 		$513K Sell
37,261
-7,062
-16% -$106K ﹤0.01% 1541
2025
Q4 		$799K Buy
44,323
+30,303
+216% +$544K ﹤0.01% 1323
2025
Q3 		$264K Buy
+14,020
New +$220K ﹤0.01% 1483
2025
Q2 		– Sell
-5,122
Closed -$96.1K – 1758
2025
Q1 		$96.1K Sell
5,122
-11
-0.2% -$232 ﹤0.01% 1752
2024
Q4 		$112K Buy
5,133
+17
+0.3% +$327 ﹤0.01% 1782
2024
Q3 		$92.8K Sell
5,116
-4,307
-46% -$63.9K ﹤0.01% 1784
2024
Q2 		$115K Buy
+9,423
New +$105K ﹤0.01% 1687

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Amundi's CLBT Position: Q2 2026 in Review

Amundi increased its Cellebrite (CLBT) stake by 42% in Q2 2026, buying an estimated $209K and bringing the position to 53,045 shares worth $774K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

Amundi first reported a position in CLBT in Q2 2024 and has held it in 8 quarters since. The position peaked at $799K in Q4 2025. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Amundi held 53,045 shares of Cellebrite worth $774K as of Q2 2026.
  • Amundi bought 15,784 Cellebrite shares in Q2 2026, an estimated $209K.
  • Cellebrite made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1480 holding.
  • Amundi first reported a position in Cellebrite in Q2 2024 and has held it in 8 quarters since.
  • Amundi's Cellebrite position peaked at $799K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.